Cisplatin News and Research

RSS

Study findings could set new standard of care for advanced anal cancer

A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.

31 Aug 2018

HKBU chemists discover metal-based inhibitor to treat triple-negative breast cancer

Chemists at Hong Kong Baptist University have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer, one of the most difficult forms of breast cancer to treat.

30 Aug 2018

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.

22 Aug 2018

Study reveals role of RUNX proteins in DNA repair

A study by researchers from the Cancer Science Institute of Singapore at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia pathway.

15 Aug 2018

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Patients with a greater than 10 pack/year history of smoking tend to develop an especially dangerous form of head and neck squamous cell cancer for which prognosis remains poor and treatments have changed little during the past two decades.

14 Aug 2018

New drug delivery system delivers anticancer drugs that reduce tumor size

Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.

9 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Study uncovers new protein complex that shields broken DNA ends

Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

19 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

A new study reveals that pediatric neuroblastoma patients are at elevated risk for long-term psychological impairment. In addition, those who experience such impairment as they get older tend to require special education services and to not go on to college.

11 Jun 2018

Colorado researchers suggest new combination therapy for advanced head and neck cancer

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab.

7 Jun 2018

International researchers succeed in stopping growth of mesothelioma in model animals

An international team led by researchers from the Technion-Israel Institute of Technology and NYU Langone Health have succeeded in stopping the growth of mesothelioma in model animals by inhibiting the heparanase enzyme.

24 May 2018

Studies show hemp's potential for treating ovarian cancer

Results from some of the first studies to examine hemp's ability to fight cancer show that it might one day be useful as plant-based treatment for ovarian cancer. Hemp is part of the same cannabis family as marijuana but doesn't have any psychoactive properties or cause addiction.

24 Apr 2018

Scientists discover new family of promising silver-based anti-cancer drugs

A new family of very promising silver-based anti-cancer drugs has been discovered by researchers in South Africa. The most promising silver thiocyanate phosphine complex among these, called UJ3 for short, has been successfully tested in rats and in human cancer cells in the laboratory.

26 Mar 2018

Cisplatin News and Research

Study findings could set new standard of care for advanced anal cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

HKBU chemists discover metal-based inhibitor to treat triple-negative breast cancer

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Study reveals role of RUNX proteins in DNA repair

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

New drug delivery system delivers anticancer drugs that reduce tumor size

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Study uncovers new protein complex that shields broken DNA ends

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

Colorado researchers suggest new combination therapy for advanced head and neck cancer

International researchers succeed in stopping growth of mesothelioma in model animals

Studies show hemp's potential for treating ovarian cancer

Scientists discover new family of promising silver-based anti-cancer drugs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News